An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system
James Larkin(Trinity College Dublin), Christian U. Blank(The Netherlands Cancer Institute), Ivana Krajsová(Charles University), Ana Arance(Hospital Clínic de Barcelona), Mario Mandalà(University of Perugia), Geke A.P. Hospers(University Medical Center Groningen), Michael P. Brown(South Australia Pathology), Jacob Schachter, Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Margarita Donica(Decision Sciences (United States)), Marta Nyakas(Oslo University Hospital), Axel Hauschild(University Hospital Schleswig-Holstein), Wilson H. Miller(Jewish General Hospital), Enrique Espinosa(Hospital Universitario La Paz), Martina Makrutzki(Roche (Switzerland)), Paul Lorigan(Manchester Academic Health Science Centre), Alex Guminski(The University of Sydney), Paola Queirolo, Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Bart Neyns(Universitair Ziekenhuis Brussel), Helen Gogas(National and Kapodistrian University of Athens), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), G. Liszkay, Claus Garbe(University of Tübingen)
Cited by 14
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
|New England Journal of Medicine|2012|5.5k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k